바이오스펙테이터

바이오스펙테이터 Seunghyun Chon 기자

Bukwang Pharmaceutical has started to enroll patients for late phase 2 clinical trial for a new diabetes substance

Bukwang pharmaceutical announced on November 11th about their patient enrollment for late phase 2 clinical trial of MLR-1023, a new drug candidate for type 2 diabetes mellitus, which is being co-developed with U.S. Melior. After recent approval of plans on clinical trial from FDA and KFDA, Bukwang pharmaceutical is now beginning to set up their clinical trials in earnest.

MLR-1023 is a candidate substance for diabetes therapy, which better improves in lowering of blood glucose by direct and selective activation of Lyn kinase that is involved in insulin cell signaling. Bukwang pharmaceutical is in progress of clinical trials since they have signed a licensing agreement with Melior for joint development of MLR-1023 in 2013.

A staff from Bukwang pharmaceutical said, “If we successfully develop MLR-1023 as an innovative drug which has completely different mechanism from that of existing diabetes treatment, I am expecting to see a huge impact on existing diabetes treatment market.”

Bukwang pharmaceutical is preparing for global clinical trial of JM-010, targeting to start in the second half of this year. JM-010 is a drug candidate developed by Contera Pharma, a subsidiary of Danish company. This substance was developed to treat movement disorders occurring in 60-70% of long-term administration of levodopa to Parkinson’s disease patients for treatment of Parkinson’s disease.

Bukwang Pharmaceutical said, “We are planning to make further efforts to find growth engine of our company through the development of innovative new drugs in the expansion to overseas markets.”